Arrowstreet Capital, Limited Partnership Fate Therapeutics Inc Transaction History

Arrowstreet Capital, Limited Partnership

  • $121 Billion
  • Q3 2024

A detailed history of Arrowstreet Capital, Limited Partnership transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 32,098 shares of FATE stock, worth $53,282. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,098
Holding current value
$53,282
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$3.12 - $5.57 $100,145 - $178,785
32,098 New
32,098 $112,000
Q4 2021

Feb 14, 2022
SELL
$47.84 - $64.34 $1.2 Million - $1.61 Million
-25,100 Closed
0 $0
Q3 2021

Nov 12, 2021
BUY
$59.27 - $95.73 $1.26 Million - $2.04 Million
21,300 Added 560.53%
25,100 $1.49 Million
Q2 2021

Aug 13, 2021
BUY
$67.25 - $92.52 $255,550 - $351,576
3,800 New
3,800 $330,000
Q1 2021

May 14, 2021
SELL
$72.16 - $117.4 $5.02 Million - $8.18 Million
-69,636 Closed
0 $0
Q4 2020

Feb 12, 2021
BUY
$38.09 - $100.95 $1.35 Million - $3.58 Million
35,477 Added 103.86%
69,636 $6.33 Million
Q3 2020

Nov 12, 2020
BUY
$30.41 - $40.5 $1.04 Million - $1.38 Million
34,159 New
34,159 $1.37 Million
Q1 2020

May 15, 2020
SELL
$17.28 - $31.88 $551,232 - $1.02 Million
-31,900 Closed
0 $0
Q4 2019

Feb 13, 2020
BUY
$13.39 - $20.73 $427,141 - $661,287
31,900 New
31,900 $624,000
Q2 2019

Aug 14, 2019
SELL
$15.61 - $20.44 $301,273 - $394,492
-19,300 Closed
0 $0
Q1 2019

May 15, 2019
BUY
$13.15 - $18.71 $112,169 - $159,596
8,530 Added 79.2%
19,300 $339,000
Q4 2018

Feb 14, 2019
BUY
$11.48 - $16.98 $123,639 - $182,874
10,770 New
10,770 $138,000

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Arrowstreet Capital, Limited Partnership Portfolio

Follow Arrowstreet Capital, Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email